KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients.CNS SpectrPMID 36226902无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理
Impact of physical activity on postural stability and coordination in children with posterior fossa tumor: randomized control phase III trial.J Cancer Res Clin OncolPMID 36525069PMC103566662023-Aug0.90Eligible trial type (randomized, phase III, oncology, human) but the reported outcomes are functional/quality-of-life measures, not the required survival or tumor-related efficacy outcomes.待处理
Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study.J Cancer Res Clin OncolPMID 36595042PMC117966712023-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study.Auris Nasus LarynxPMID 36599786无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.J Cancer Res Clin OncolPMID 36680581PMC98644992023-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study.Am J OphthalmolPMID 36948372无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理
Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03.Qual Life ResPMID 37020153PMC103308912023-Aug0.90The record is a methodological study of a patient-reported outcome instrument developed for a Phase III trial, not a report of the trial's efficacy results. It lacks a drug intervention and a time-to-event efficacy endpoint.待处理
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.Transplant Cell TherPMID 37120136无 PMCID2023-Aug0.95The record is a Phase III randomized trial of a drug-containing intervention (omidubicel) in an oncology setting, but the specific report is a secondary substudy analyzing immune reconstitution and viral infection rates, not reporting a primary time-to-event efficacy endpoint (e.g., OS, PFS) or Kaplan-Meier/HR results for such an endpoint. Therefore, it does not meet the inclusion criteria for a primary or key secondary efficacy endpoint analysis.待处理
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2).Ann Surg OncolPMID 37170037PMC106877432023-Aug0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.Eur UrolPMID 37179241PMC106626422023-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.Cancer SciPMID 37183528PMC103941352023-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.Urol OncolPMID 37198025无 PMCID2023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Radiotherapy for Ledderhose disease: Results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial.Radiother OncolPMID 37211283无 PMCID2023-Aug0.90The study is a randomized phase III trial with original results, but it is excluded because it is not oncology (it treats non-malignant Ledderhose disease) and does not involve a drug-containing intervention or a time-to-event efficacy endpoint.待处理
Long-term effectiveness of a novel intra-oral electro-stimulator for the treatment of dry mouth in patients with Sjogren's syndrome: A randomised sham-controlled feasibility study (LEONIDAS-1).J Oral Pathol MedPMID 37220073PMC109467572023-Aug0.98未发现恶性肿瘤人群证据。待处理
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.Amyotroph Lateral Scler Frontotemporal DegenerPMID 37254449无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.Gynecol OncolPMID 37262961无 PMCID2023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.Eur J CancerPMID 37263896无 PMCID2023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Development and evaluation of DiabeText, a personalized mHealth intervention to support medication adherence and lifestyle change behaviour in patients with type 2 diabetes in Spain: A mixed-methods phase II pragmatic randomized controlled clinical trial.Int J Med InformPMID 37267809无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.Ann OncolPMID 37268157无 PMCID2023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.Eur J CancerPMID 37277264无 PMCID2023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.Cancer MedPMID 37325938PMC104696382023-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients.Clin Breast CancerPMID 37336651无 PMCID2023-Aug0.90The record describes a phase III randomized trial in oncology with drug intervention, but the analysis presented is a secondary/biomarker analysis focusing on the association between obesity and circulating tumor cells. The endpoint is CTC positivity (a binary/prognostic factor), not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the required time-to-event efficacy endpoint criterion for inclusion in the KM cohort.待处理
A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.Br J HaematolPMID 37339869无 PMCID2023-Aug0.99记录类型属于综述、Meta 分析、社论、评论、病例或指南。待处理
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.Lancet HaematolPMID 37385272PMC105288092023-Aug0.98未发现恶性肿瘤人群证据。待处理
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.ESMO OpenPMID 37390764PMC104854032023-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.Cancer Commun (Lond)PMID 37403255PMC103975612023-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.Lancet HaematolPMID 37414062无 PMCID2023-Aug0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.Lancet OncolPMID 37423227无 PMCID2023-Aug0.85The trial is a phase 3 randomized controlled trial in human oncology with original results. However, it is not eligible because it does not have a drug-containing intervention (the intervention is a radiotherapy technique, DO-IMRT vs standard IMRT) and its primary endpoint is a patient-reported quality-of-life measure (MDADI score), not a time-to-event efficacy endpoint like OS, PFS, or DFS.待处理
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.Lancet HIVPMID 37451297无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理
Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.J NeurooncolPMID 37452916无 PMCID2023-Aug0.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.Nat MedPMID 37524953PMC104274182023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
[First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO].Aktuelle UrolPMID 37541235无 PMCID2023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens.ESMO OpenPMID 37542912PMC104853932023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials.JCO Clin Cancer InformPMID 37552823无 PMCID2023-Aug0.90The study is a bibliometric analysis of Phase III cancer RCTs, not a report of clinical outcomes from such a trial.待处理
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.RMD OpenPMID 37604638PMC104453772023-Aug0.98未发现恶性肿瘤人群证据。待处理
Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.RMD OpenPMID 37652554PMC104761192023-Aug0.98未发现恶性肿瘤人群证据。待处理
A multicenter randomized, controlled clinical trial of adjuvant sintilimab for esophageal squamous cell carcinoma.Future OncolPMID 37737025无 PMCID2023-Aug0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.Lancet RheumatolPMID 38251577无 PMCID2023-Aug0.98未发现恶性肿瘤人群证据。待处理
Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.Jpn J Clin OncolPMID 37282626无 PMCID2023-Jul-310.45The record is a review article summarizing multiple trials, not an original result report of a single randomized trial. It lacks primary time-to-event efficacy data (e.g., KM curves, HR) for any specific trial, which is required for eligibility.待处理
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033).VaccinePMID 37344262无 PMCID2023-Jul-310.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.LancetPMID 37311468无 PMCID2023-Jul-290.85The trial is an oncology Phase 3 randomized study with a drug intervention and original results, but the primary efficacy endpoint is a categorical response (transfusion independence with Hb increase), not a time-to-event endpoint. Therefore, it does not meet the time-to-event requirement for inclusion.待处理
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J MedPMID 37272512无 PMCID2023-Jul-270.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.N Engl J MedPMID 37356066无 PMCID2023-Jul-270.98未发现恶性肿瘤人群证据。待处理
[Comparison of the effects and safety of dydrogesterone and medroxyprogesterone acetate on endometrial hyperplasia without atypia: a randomized controlled non-inferior phase Ⅲ clinical study].Zhonghua Fu Chan Ke Za ZhiPMID 37474326无 PMCID2023-Jul-250.98未发现恶性肿瘤人群证据。待处理
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.LancetPMID 37285865无 PMCID2023-Jul-220.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.N Engl J MedPMID 37272521无 PMCID2023-Jul-200.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.NeurologyPMID 37268435PMC103822592023-Jul-180.98未发现恶性肿瘤人群证据。待处理
Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.JAMAPMID 37354562PMC103546852023-Jul-180.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial.Virol JPMID 37464440PMC103550352023-Jul-180.98未发现恶性肿瘤人群证据。待处理
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.CancerPMID 37151113无 PMCID2023-Jul-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理